DDInter1747 DDInter1427
Tasimelteon is a selective dual melatonin receptor agonist indicated for the treatment of Non-24-Hour Sleep-Wake Disorder (N24HSWD). Occurring commonly in blind individuals without light perception, this condition is often characterized by periods of night-time insomnia and day-time sleepiness. In blind individuals, a lack of light stimulation causes an extension of the 24-hour circadian cycle and can lead to progressively delayed sleep onset. By activating melatonin receptors MT1 and MT2 in the suprachiasmatic nucleus of the brain, tasimelteon has been shown to improve sleep by resynchronizing the circadian rhythm through its "non-photic" mechanism. Tasimelteon is currently the only drug available for the treatment of N24HSWD and was granted orphan drug status by the FDA in 2010.
Pentoxyverine, also referred to as carbetapentane, is a non-opioid central acting antitussive with antimuscarinic, anticonvulsant , and local anesthetic properties. It is an active ingredient in over-the-counter cough suppressants in combination with guaifenesin and H1-receptor antagonists . Pentoxyverine acts on sigma-1 receptors, as well as kappa and mu-opioid receptors. The FDA withdrew the use of all oral gel drug products containing pentoxyverine citrate. Other forms of pentoxyverine citrate continue to be marketed.
Pentoxyverine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Nalbuphine
Pentoxyverine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Brexanolone
Pentoxyverine {u} may lead to a major life threatening interaction when taken with {v} Rasagiline
Pentoxyverine may cause a moderate interaction that could exacerbate diseases when taken with Nalbuphine
Pentoxyverine may cause a moderate interaction that could exacerbate diseases when taken with Brexanolone
Pentoxyverine may lead to a major life threatening interaction when taken with Rasagiline